In today’s recent session, 0.93 million shares of the Lineage Cell Therapeutics Inc (AMEX:LCTX) have been traded, and its beta is 1.51. Most recently the company’s share price was $0.69, and it changed around -$0.01 or -0.76% from the last close, which brings the market valuation of the company to $158.34M. LCTX at last check was trading at a discount to its 52-week high of $1.15, offering almost -66.67% off that amount. The share price’s 52-week low was $0.37, which indicates that the recent value has risen by an impressive 46.38% since then. We note from Lineage Cell Therapeutics Inc’s average daily trading volume that its 10-day average is 1.15 million shares, with the 3-month average coming to 1.34 million.
Lineage Cell Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.43. If we narrow it down even further, the data shows that 0 out of 7 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 1 recommended LCTX as a Hold, whereas 4 deemed it a Buy, and 0 rated it as Underweight. Lineage Cell Therapeutics Inc is expected to report earnings per share of -0.03 for the current quarter.
Lineage Cell Therapeutics Inc (AMEX:LCTX) trade information
Instantly LCTX has been showing red trend so far today with a performance of -0.76% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.7600 on recent trading dayincreased the stock’s daily price by 9.21%. The company’s shares are currently up 37.99% year-to-date, but still up 39.40% over the last five days. On the other hand, Lineage Cell Therapeutics Inc (AMEX:LCTX) is 41.51% up in the 30-day period. We can see from the shorts that 30.0 million shares have been sold at a short interest cover period of 23.99 day(s).
Lineage Cell Therapeutics Inc (LCTX) estimates and forecasts
The year-over-year growth rate is expected to be -29.48%, down from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 1.47M in revenue for the current quarter. 7 analysts expect Lineage Cell Therapeutics Inc to make 1.89M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 1.41M and 3.78M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 4.59%. Forecasts for the next quarter put sales growth at -50.02%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -2.93%. Lineage Cell Therapeutics Inc earnings are expected to increase by -9.73% in 2025, but the outlook is positive 9.01% per year for the next five years.
LCTX Dividends
Lineage Cell Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-May-12.
Lineage Cell Therapeutics Inc (AMEX:LCTX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.42% of Lineage Cell Therapeutics Inc shares, and 47.93% of them are in the hands of institutional investors. The stock currently has a share float of 48.14%. Lineage Cell Therapeutics Inc stock is held by 157.0 institutions, with BROADWOOD CAPITAL INC being the largest institutional investor. By 2024-06-30, it held 22.0675% of the shares, which is about 41.67 million shares worth $41.55 million.
BLACKROCK INC., with 5.0629% or 9.56 million shares worth $9.53 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
iShares Trust-iShares Russell 2000 ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 4.53 shares worth $3.13 million, making up 1.98% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 4.42 shares worth around $3.05 million, which represents about 1.93% of the total shares outstanding.
